TrumpRx Is a Prescription for Failure

In a recent article for RealClearHealth, Market Institute President Charles Sauer warns that the Trump administration’s new TrumpRx initiative may deliver lower drug prices in the short run—but at the cost of future medical innovation. Sauer explains that while the goal of lowering pharmaceutical prices is laudable, the method matters. Read more…

The FTC Should Roll Back the Administrative State

Independent federal agencies were a hallmark of the Progressive Era, designed to operate at arm’s length from elected officials. Over time, however, many of these agencies have accumulated powers that raise serious constitutional concerns—writing rules, enforcing them, and adjudicating disputes internally. In a recent RealClearMarkets piece, Charles Sauer argues that Read more…